Tempest Therapeutics Inc (TPST) - Total Liabilities
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has total liabilities worth $9.93 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Tempest Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Tempest Therapeutics Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Tempest Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TPST total asset value.
Tempest Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tempest Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orpheus Uranium Ltd
AU:ORP
|
Australia | AU$234.19K |
|
Ecolomondo Corp
V:ECM
|
Canada | CA$53.40 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
Korea | ₩79.62 Billion |
|
Daedong Steel Co. Ltd
KQ:048470
|
Korea | ₩25.08 Billion |
|
Seven Principles AG
XETRA:T3T1
|
Germany | €12.81 Million |
|
Maternus-Kliniken Aktiengesellschaft
F:MAK
|
Germany | €230.46 Million |
|
OptiCept Technologies AB
ST:OPTI
|
Sweden | Skr89.91 Million |
|
FILL UP MEDIA EO -25
F:X3D
|
Germany | €24.62 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Tempest Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TPST equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 12.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tempest Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tempest Therapeutics Inc (2011–2025)
The table below shows the annual total liabilities of Tempest Therapeutics Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.26 Million | -54.11% |
| 2024-12-31 | $22.36 Million | -9.96% |
| 2023-12-31 | $24.84 Million | -11.23% |
| 2022-12-31 | $27.98 Million | -24.63% |
| 2021-12-31 | $37.12 Million | -59.50% |
| 2020-12-31 | $91.66 Million | +507.03% |
| 2019-12-31 | $15.10 Million | +37.87% |
| 2018-12-31 | $10.95 Million | +126.80% |
| 2017-12-31 | $4.83 Million | -66.29% |
| 2016-12-31 | $14.32 Million | +21.78% |
| 2015-12-31 | $11.76 Million | +14.79% |
| 2014-12-31 | $10.25 Million | +75.34% |
| 2013-12-31 | $5.84 Million | +179.22% |
| 2012-12-31 | $2.09 Million | +174.67% |
| 2011-12-31 | $762.00K | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more